Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more
Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
We conduct clinical research and investigations to improve our ability to diagnose and treat patients with all genitourinary malignancies. This research is important, because it aims to improve current and future cancer treatments and care.
Our physicians and researchers conduct ongoing research studies, including:
If you are a new patient, we may ask you to participate in one of these studies.
Learn more about participating in a clinical trial.
As a Dana-Farber patient, you may be asked to participate in a research study designed to help doctors and scientists understand the basic biology and genetics of prostate and renal cancer, which ultimately may help people in the future.
During your appointment, a study coordinator will meet with you to discuss the study and answer your questions. Your participation is completely voluntary and will not affect your medical care or benefits should you decide not to participate.
Find out more about prostate, bladder, and kidney cancer research studies.
With the cooperation of more than 8,000 patients, the Arthur and Linda Gelb Center for Translational Research has steadily built a deep clinical database and collection of genitourinary tumor samples.
Research using these samples has yielded significant data about the development and treatment of prostate, kidney, and bladder cancers, helping scientists study possible links between genes and genitourinary cancers.
Such efforts are designed to develop better, more effective treatments for cancer and related malignancies.
Learn more about the Gelb Center.
Trial 19-897: An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1/L1 and VEGF-Targeted Therapies Principal investigator: Toni Choueiri, MD
Trial 19-140: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Apalutamide in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy Principal investigator: Mary-Ellen Taplin, MD
Trial 18-649: A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post-Surgery Therapy with Nivolumab or Nivolumab and BMS-986205 in Participants with Muscle-Invasive Bladder Cancer Principal Investigator: Guru Sonpavde, MD
New Patient Appointments
Rare Genitourinary CancersImagine having a cancer so rare, trials don't exist for you. That's been the case for years for patients with certain genitourinary cancers. Now, a first of its kind trial at Dana-Farber Cancer Institute offers a potential turning point and the opportunity to try a promising therapy.
Clinical Trials Questions?